Navigation Links
Fuisz Pharma Announces Patent Allowance For New Tablet And Caplet Shapes That Promote Rapid, Reliable Esophageal Transit
Date:1/23/2013

MIAMI, Jan. 23, 2013 /PRNewswire/ -- Fuisz Pharma LLC announced today that it has received a notice of allowance from the United States Patent and Trademark Office in connection with its utility patent application entitled "Solid Dosage Form That Promotes Reliable Oral, Esophageal and GI Transit" (US 20120141545).  The allowed claims cover Fuisz Pharma's new tablet and caplet designs for improved transit, including the tablet that Fuisz Pharma calls the "Saturn™".  The Saturn™ has been demonstrated through in vitro tests and in vivo clinical trials to enable easier swallowing and more reliable, faster esophageal clearance as compared with conventional tablet shapes.  A photo of the Saturn™ is included below.

(Photo: http://photos.prnewswire.com/prnh/20130123/PH46501)

Joseph Fuisz , Managing Member, stated, "This allowance of patent claims around our Saturn™ tablet has important therapeutic and commercial implications."

The Saturn™ tablet offers a great benefit through its faster and more reliable esophageal transit.   The high frequency of esophageal transit failure is increasingly understood.  Moreover, the breadth of drug classes that provoke esophageal irritation is increasingly understood to extend far beyond the bisphosphonates as is manifest from the FDA's adverse event reporting system, including cox-2, statins and NSAIDs.  Moreover, esophageal transit failure results in delayed C(max) – with one published study showing C(max) in supine patients with an average C(max) delay of seventy minutes.

Importantly for Fuisz Pharma, the FDA is increasingly recognizing the role of tablet shape in esophageal transit with a view towards requiring generics to follow the size and shape of the reference, branded product.

This patent allowance and the underlying invention can enable a therapeutically superior product with robust, fresh patent protection.  Yet, the adoption of Saturn™ will generally require no formulation change and offers a concise, clear regulatory path (through post approval supplement 21 CFR 314.70 and 314.71).  The Saturn™ is simply made using a new tablet die which Fuisz has already vetted.  Thus, the Saturn™ offers a compelling proposition for industry adoption."

Dr. Richard Fuisz , Founding Member of Fuisz Pharma (http://en.wikipedia.org/wiki/Richard_Fuisz), commented, "I am personally very proud, with my son Joseph, of this invention. There are many reasons for that pride. Firstly, the product makes possible a dramatic improvement in health care. You must get the dosage unit to its effective site in order to get proper blood levels. The most sophisticated pharmacology and the most sophisticated analytical methods, are meaningless if the drug does not pass to its absorptive site.  Secondly, at age 73, I am proud to once again prove that it is the focus and perseverance of the individual that makes progress. Often forgotten in an era when success is, too often by the younger generation, thought to be synonymous with big venture capital and large, filled parking lots. If you are a small inventor reading this: take heart, you may well have the advantage."

Fuisz Pharma is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma.  Fuisz Pharma is also active in diagnostic systems.  Fuisz Pharma has its headquarters in Miami and is not affiliated with MonoSol Rx. www.fuisz.com.


'/>"/>
SOURCE Fuisz Pharma LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AAIPharma Expands Laboratory Service Offerings and Capabilities in its Technology Center
2. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
3. Harris Poll Study Links Emotional Connection to Physicians Trust in Pharmaceutical Products
4. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Shanghai Celgen
5. Ampio Pharmaceuticals Announces Participation at Upcoming Investor Conference
6. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
7. Robust Biopharmaceutical Pipeline Offers New Hope for Patients
8. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
9. Collegium Pharmaceutical Announces Relocation to Massachusetts
10. Pharmaceuticals: Global Industry Guide
11. Academy of Managed Care Pharmacy Collaborates with National Association of Specialty Pharmacy to Host Inaugural AMCP/NASP Specialty Pharmacy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in post-acute health care, have expanded their existing home health joint venture through ... AccentCare has been operating a joint venture home health company with Asante, delivering ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer Dr. ... colleagues, skilled nursing facility medical directors and other clinicians at various events in ... , "At many of these conferences we get to educate other physicians, facility ...
Breaking Medicine News(10 mins):